Please enable JavaScript to continue using this application.

Compare $PYXS vs $STRO | Chartloom

Compare

$PYXS vs $STRO

Pyxis Oncology Inc · Sutro Biopharma Inc

PYXS

Pyxis Oncology Inc

STRO

Sutro Biopharma Inc

Compare $PYXS vs $STRO

Comparing Pyxis Oncology Inc and Sutro Biopharma Inc

PYXSPyxis Oncology Inc

STROSutro Biopharma Inc

PYXSPyxis Oncology Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-14.2%

YTD performance

76.5%

52W performance

-30.2%

FCF yield

-40.3%

STROSutro Biopharma Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.01x

Rev growth (TTM)

-56.3%

YTD performance

30.2%

52W performance

67.2%

FCF yield

-61.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PYXS

STRO

Detailed metrics comparison

PYXS

Pyxis Oncology Inc

STRO

Sutro Biopharma Inc

Market Cap

PYXS$168M

STRO$236M

Enterprise Value

PYXS$150M

STRO$421M

Price

PYXS$2.03

STRO$14.27

P/E Ratio

PYXSN/A

STRON/A

P/S Ratio

PYXS15.26x

STRO5.17x

EV/Sales

PYXS13.55x

STRO9.22x

EV/EBITDA

PYXS0.00x

STRO0.00x

P/B Ratio

PYXS15.60x

STRO5.78x

P/FCF Ratio

PYXSN/A

STRON/A

EV/FCF

PYXS-2.20x

STRO-2.89x

PEG Ratio

PYXSN/A

STRON/A

Forward P/E (NTM)

PYXSN/A

STRON/A

Forward P/S (NTM)

PYXSN/A

STRO6.01x

Revenue (TTM)

PYXS$11M

STRO$46M

Revenue Growth (YoY)

PYXS-14.2%

STRO-56.3%

Forward Rev Growth

PYXS14187.3%

STRO-19.2%

Gross Margin (TTM)

PYXS78.4%

STRO0.0%

Operating Margin (TTM)

PYXS0.0%

STRO0.0%

EBITDA Margin (TTM)

PYXS-580.0%

STRO-275.3%

Net Margin (TTM)

PYXS-593.0%

STRO-395.2%

FCF Margin (TTM)

PYXS-615.3%

STRO-318.6%

Net Income (TTM)

PYXS$-65M

STRO$-181M

FCF (TTM)

PYXS$-68M

STRO$-146M

EPS (TTM)

PYXS-$1.03

STRO-$10.90

ROE (TTM)

PYXS-10177.0%

STRO-22384.0%

ROA (TTM)

PYXS-6981.0%

STRO-8812.0%

ROIC (TTM)

PYXS-10171.0%

STRO-22384.0%

Cash

PYXS$19M

STRO$54M

Debt

PYXS$0

STRO$239M

Net Cash/Debt

PYXS$19M

STRO$-185M

Current Ratio (TTM)

PYXS1.34x

STRO3.32x

Quick Ratio (TTM)

PYXS1.25x

STRO3.22x

Debt/Equity (TTM)

PYXS0.00x

STRO4.05x

Debt/Assets (TTM)

PYXS0.0%

STRO0.0%

Interest Coverage (TTM)

PYXSN/A

STRON/A

Net Debt/EBITDA (TTM)

PYXS0.00x

STRO0.00x

Beta

PYXS1.37

STRO1.47

52W Performance

PYXS-30.2%

STRO67.2%

YTD Performance

PYXS76.5%

STRO30.2%

% from 52W High

PYXS-63.4%

STRO-67.5%

% from 52W Low

PYXS97.1%

STRO99.6%

Asset Turnover (TTM)

PYXS0.00x

STRO0.22x

FCF Yield (TTM)

PYXS-40.3%

STRO-61.6%

Earnings Yield (TTM)

PYXS-38.9%

STRO-76.4%

Dividend Yield (TTM)

PYXSN/A

STRON/A

Rule of 40

PYXS-629.5

STRO-374.9

EV/GP/RG

PYXS0.00

STRON/A

Ticker research

View PYXS research View STRO research

Metric	PYXS Pyxis Oncology Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$168M	$236M
Enterprise Value	$150M	$421M
Price	$2.03	$14.27
P/E Ratio	N/A	N/A
P/S Ratio	15.26x	5.17x
EV/Sales	13.55x	9.22x
EV/EBITDA	0.00x	0.00x
P/B Ratio	15.60x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-2.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.01x
Revenue & Growth
Revenue (TTM)	$11M	$46M
Revenue Growth (YoY)	-14.2%	-56.3%
Forward Rev Growth	14187.3%	-19.2%
Profitability
Gross Margin (TTM)	78.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-580.0%	-275.3%
Net Margin (TTM)	-593.0%	-395.2%
FCF Margin (TTM)	-615.3%	-318.6%
Net Income (TTM)	$-65M	$-181M
FCF (TTM)	$-68M	$-146M
EPS (TTM)	-$1.03	-$10.90
ROE (TTM)	-10177.0%	-22384.0%
ROA (TTM)	-6981.0%	-8812.0%
ROIC (TTM)	-10171.0%	-22384.0%
Financial Health
Cash	$19M	$54M
Debt	$0	$239M
Net Cash/Debt	$19M	$-185M
Current Ratio (TTM)	1.34x	3.32x
Quick Ratio (TTM)	1.25x	3.22x
Debt/Equity (TTM)	0.00x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.37	1.47
52W Performance	-30.2%	67.2%
YTD Performance	76.5%	30.2%
% from 52W High	-63.4%	-67.5%
% from 52W Low	97.1%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.22x
FCF Yield (TTM)	-40.3%	-61.6%
Earnings Yield (TTM)	-38.9%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-629.5	-374.9
EV/GP/RG	0.00	N/A
Ticker research	View PYXS research	View STRO research

Valuation

P/S Ratio

STRO

5.17x

PYXS

15.26x

EV/FCF

STRO

-2.89x

PYXS

-2.20x

Growth & revenue

Revenue Growth TTM

PYXS

-14.2%

STRO

-56.3%

Forward Revenue Growth

PYXS

14187.3%

STRO

-19.2%

Profitability & performance

Gross Margin

PYXS

78.4%

STRO

0.0%

ROE

PYXS

-10177.0%

STRO

-22384.0%

FCF Yield %

PYXS

-40.3%

STRO

-61.6%

52-Week Performance

STRO

67.2%

PYXS

-30.2%

Detailed metrics comparison

PYXS

Pyxis Oncology Inc

STRO

Sutro Biopharma Inc

Market Cap

PYXS$168M

STRO$236M

Enterprise Value

PYXS$150M

STRO$421M

Price

PYXS$2.03

STRO$14.27

P/E Ratio

PYXSN/A

STRON/A

P/S Ratio

PYXS15.26x

STRO5.17x

EV/Sales

PYXS13.55x

STRO9.22x

EV/EBITDA

PYXS0.00x

STRO0.00x

P/B Ratio

PYXS15.60x

STRO5.78x

P/FCF Ratio

PYXSN/A

STRON/A

EV/FCF

PYXS-2.20x

STRO-2.89x

PEG Ratio

PYXSN/A

STRON/A

Forward P/E (NTM)

PYXSN/A

STRON/A

Forward P/S (NTM)

PYXSN/A

STRO6.01x

Revenue (TTM)

PYXS$11M

STRO$46M

Revenue Growth (YoY)

PYXS-14.2%

STRO-56.3%

Forward Rev Growth

PYXS14187.3%

STRO-19.2%

Gross Margin (TTM)

PYXS78.4%

STRO0.0%

Operating Margin (TTM)

PYXS0.0%

STRO0.0%

EBITDA Margin (TTM)

PYXS-580.0%

STRO-275.3%

Net Margin (TTM)

PYXS-593.0%

STRO-395.2%

FCF Margin (TTM)

PYXS-615.3%

STRO-318.6%

Net Income (TTM)

PYXS$-65M

STRO$-181M

FCF (TTM)

PYXS$-68M

STRO$-146M

EPS (TTM)

PYXS-$1.03

STRO-$10.90

ROE (TTM)

PYXS-10177.0%

STRO-22384.0%

ROA (TTM)

PYXS-6981.0%

STRO-8812.0%

ROIC (TTM)

PYXS-10171.0%

STRO-22384.0%

Cash

PYXS$19M

STRO$54M

Debt

PYXS$0

STRO$239M

Net Cash/Debt

PYXS$19M

STRO$-185M

Current Ratio (TTM)

PYXS1.34x

STRO3.32x

Quick Ratio (TTM)

PYXS1.25x

STRO3.22x

Debt/Equity (TTM)

PYXS0.00x

STRO4.05x

Debt/Assets (TTM)

PYXS0.0%

STRO0.0%

Interest Coverage (TTM)

PYXSN/A

STRON/A

Net Debt/EBITDA (TTM)

PYXS0.00x

STRO0.00x

Beta

PYXS1.37

STRO1.47

52W Performance

PYXS-30.2%

STRO67.2%

YTD Performance

PYXS76.5%

STRO30.2%

% from 52W High

PYXS-63.4%

STRO-67.5%

% from 52W Low

PYXS97.1%

STRO99.6%

Asset Turnover (TTM)

PYXS0.00x

STRO0.22x

FCF Yield (TTM)

PYXS-40.3%

STRO-61.6%

Earnings Yield (TTM)

PYXS-38.9%

STRO-76.4%

Dividend Yield (TTM)

PYXSN/A

STRON/A

Rule of 40

PYXS-629.5

STRO-374.9

EV/GP/RG

PYXS0.00

STRON/A

Ticker research

View PYXS research View STRO research

Metric	PYXS Pyxis Oncology Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$168M	$236M
Enterprise Value	$150M	$421M
Price	$2.03	$14.27
P/E Ratio	N/A	N/A
P/S Ratio	15.26x	5.17x
EV/Sales	13.55x	9.22x
EV/EBITDA	0.00x	0.00x
P/B Ratio	15.60x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-2.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.01x
Revenue & Growth
Revenue (TTM)	$11M	$46M
Revenue Growth (YoY)	-14.2%	-56.3%
Forward Rev Growth	14187.3%	-19.2%
Profitability
Gross Margin (TTM)	78.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-580.0%	-275.3%
Net Margin (TTM)	-593.0%	-395.2%
FCF Margin (TTM)	-615.3%	-318.6%
Net Income (TTM)	$-65M	$-181M
FCF (TTM)	$-68M	$-146M
EPS (TTM)	-$1.03	-$10.90
ROE (TTM)	-10177.0%	-22384.0%
ROA (TTM)	-6981.0%	-8812.0%
ROIC (TTM)	-10171.0%	-22384.0%
Financial Health
Cash	$19M	$54M
Debt	$0	$239M
Net Cash/Debt	$19M	$-185M
Current Ratio (TTM)	1.34x	3.32x
Quick Ratio (TTM)	1.25x	3.22x
Debt/Equity (TTM)	0.00x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.37	1.47
52W Performance	-30.2%	67.2%
YTD Performance	76.5%	30.2%
% from 52W High	-63.4%	-67.5%
% from 52W Low	97.1%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.22x
FCF Yield (TTM)	-40.3%	-61.6%
Earnings Yield (TTM)	-38.9%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-629.5	-374.9
EV/GP/RG	0.00	N/A
Ticker research	View PYXS research	View STRO research